- Home
- CYCU vs ENVB Comparison
CYCU vs ENVB Comparison
Compare CYCU & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYCU | ENVB |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | United States |
| Employees | 74 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 8.1M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CYCU | ENVB |
|---|---|---|
| Price | $0.63 | $1.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 602.4K | 130.6K |
| Earning Date | 06-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | $8.92 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $0.56 |
| 52 Week High | $7.13 | $13.25 |
Technical Indicators
Market Signals| Indicator | CYCU | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 34.56 | 28.19 |
| Support Level | $0.58 | $0.58 |
| Resistance Level | $1.05 | $2.13 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 10.58 | 8.59 |
Price Performance
Historical ComparisonAbout CYCU Cycurion Inc.
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.